Inside Tempus AI's $1.5B Personalis Deal: MRD Market Entry, Synergies, and Deal Mechanics
TEM sits 16% above its 52-week low of $41.73.
Summary
Tempus AI's investor deck on the Personalis acquisition unpacks the strategic logic, commercial metrics, and deal mechanics behind the $1.5 billion all-stock transaction, spotlighting a massive MRD market opportunity and early commercial momentum.
Key Events · M&A and Partnerships · TEM
-
Acquisition of Personalis for $1.5B
Tempus AI will acquire all outstanding shares of Personalis not already owned at $16.25 per share, a 6% premium to the July 17 close and 28% premium to the unaffected 30-day VWAP, for a total transaction value of $1.7 billion ($1.5 billion net of existing ownership).
-
Strategic Entry into $20B+ MRD Market
The deal expands Tempus into the molecular residual disease (MRD) testing market with Personalis's ultrasensitive NeXT Personal Dx, a whole-genome, tumor-informed assay detecting recurrence up to 15 months earlier than imaging with >99% sensitivity.
-
Commercial Infrastructure Leverage
Tempus's established network — connected to ~65% of U.S. academic medical centers and >55% of oncologists — will accelerate Personalis test volumes, which grew 33% sequentially in Q2 2026 to 10,384 tests, with only ~10% of Tempus's sales force currently selling the product.
-
Deal Terms and Exchange Ratio Cap
Consideration is a mix of Tempus stock and up to 50% cash at Tempus's discretion, with a floating exchange ratio capped at 0.3356x. Personalis can terminate if Tempus's stock falls below $46.00 before closing, expected in Q4 2026 at earliest.
Analysis · TEM · Industrial Applications And Services
The investor presentation on the Personalis acquisition lays out the strategic rationale for the $1.5 billion transaction: a direct path into the $20+ billion MRD market via an ultrasensitive test, amplified by Tempus's commercial reach—where only about 10% of the sales force currently sells Personalis's NeXT Personal Dx. The deck quantifies the momentum with 33% sequential quarterly test volume growth, more than 35,000 tests delivered, and advancing reimbursement. It also clarifies the deal structure, including a floating exchange ratio capped at 0.3356x and a termination right triggered if Tempus stock falls below $46.00. What was a headline acquisition now reads as a concrete growth narrative with measurable commercial traction.
At the time of this filing, TEM was trading at $48.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $41.73 to $104.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.